{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:28:11Z","timestamp":1788827291824,"version":"build-2803163510"},"reference-count":185,"publisher":"Bentham Science Publishers Ltd.","issue":"4","funder":[{"DOI":"10.13039\/501100001809","name":"Junta de Extremadura, M\u00e9rida, Spain","doi-asserted-by":"publisher","award":["GR18007"],"award-info":[{"award-number":["GR18007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2019,6,11]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>In the past two decades, a great body of research has been published regarding the effects of genetic polymorphisms on methotrexate (MTX)-induced toxicity and efficacy. Of particular interest is the role of this compound in childhood acute lymphoblastic leukaemia (ALL), where it is a pivotal drug in the different treatment protocols, both at low and high doses. MTX acts on a variety of target enzymes in the folates cycle, as well as being transported out and into of the cell by several transmembrane proteins.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>We undertook a structured search of bibliographic databases for peer-reviewed research literature using a focused review question.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>This review has intended to summarize the current knowledge concerning the clinical impact of polymorphisms in enzymes and transporters involved in MTX disposition and mechanism of action on paediatric patients with ALL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>In this work, we describe why, in spite of the significant research efforts, pharmacogenetics findings in this setting have not yet found their way into routine clinical practice.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389200220666190130161758","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T11:06:29Z","timestamp":1549019189000},"page":"313-330","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Clinical Implications of Methotrexate Pharmacogenetics in Childhood Acute Lymphoblastic Leukaemia"],"prefix":"10.2174","volume":"20","author":[{"given":"Guillermo","family":"Gervasini","sequence":"first","affiliation":[{"name":"Department of Medical & Surgical Therapeutics, Medical School, University of Extremadura, Av. Elvas s\/n 06006, Badajoz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Mota-Zamorano","sequence":"additional","affiliation":[{"name":"Department of Medical & Surgical Therapeutics, Medical School, University of Extremadura, Av. Elvas s\/n 06006, Badajoz, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"e2016024","DOI":"10.4084\/mjhid.2016.024","volume":"8","author":"Rocha J.M.","year":"2016","unstructured":"Rocha JM, Xavier SG, De Lima Souza ME, Assumpcao JG, Murao M, De Oliveira BM. Current strategies for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"e577","DOI":"10.1038\/bcj.2017.53","volume":"7","author":"Terwilliger T.","year":"2017","unstructured":"Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: A comprehensive review and 2017 update.","journal-title":"Blood Cancer J"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"Hunger S.P.","year":"2015","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children.","journal-title":"N Engl J Med"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/MPH.0000000000000206","volume":"36","author":"Schmiegelow K.","year":"2014","unstructured":"Schmiegelow K, Nielsen SN, Frandsen TL, Nersting J. Mercaptopurine\/methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: Clinical facts and fiction.","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1365-2141.2009.07765.x","volume":"146","author":"Schmiegelow K.","year":"2009","unstructured":"Schmiegelow K. Advances in individual prediction of methotrexate toxicity: A review.","journal-title":"Br J Haematol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.critrevonc.2012.04.003","volume":"84","author":"Vagace J.M.","year":"2012","unstructured":"Vagace JM, de la Maya MD, Caceres-Marzal C, Gonzalez De Murillo S, Gervasini G. Central nervous system chemotoxicity during treatment of pediatric acute lymphoblastic leukemia\/lymphoma.","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1056\/NEJMra052603","volume":"354","author":"Pui C.H.","year":"2006","unstructured":"Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia.","journal-title":"N Engl J Med"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.gpb.2016.11.003","volume":"15","author":"Rudin S.","year":"2017","unstructured":"Rudin S, Marable M, Huang RS. The promise of pharmacogenomics in reducing toxicity during acute lymphoblastic leukemia maintenance treatment.","journal-title":"Genomics Proteomics Bioinformatics"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.2217\/pgs.14.106","volume":"15","author":"Lopez-Lopez E.","year":"2014","unstructured":"Lopez-Lopez E, Gutierrez-Camino A, Bilbao-Aldaiturriaga N, Pombar-Gomez M, Martin-Guerrero I, Garcia-Orad A. Pharmacogenetics of childhood acute lymphoblastic leukemia.","journal-title":"Pharmacogenomics"},{"key":"ref=10","first-page":"3790","volume":"55","author":"Moscow J.A.","year":"1995","unstructured":"Moscow JA, Gong M, He R, Sgagias MK, Dixon KH, Anzick SL, Meltzer PS, Cowan KH. Isolation of a gene encoding a human reduced folate carrier (rfc1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells.","journal-title":"Cancer Res"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1124\/dmd.108.024315","volume":"37","author":"Van De Steeg E.","year":"2009","unstructured":"Van De Steeg E, Van Der Kruijssen CM, Wagenaar E, Burggraaff JE, Mesman E, Kenworthy KE, Schinkel AH. Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1b1 (slco1b1).","journal-title":"Drug Metab Dispos"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1001\/archinte.159.21.2542","volume":"159","author":"Strand V.","year":"1999","unstructured":"Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, Fox R, Moreland L, Olsen N, Furst D, Caldwell J, Kaine J, Sharp J, Hurley F, Loew-Friedrich I. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide rheumatoid arthritis investigators group.","journal-title":"Arch Intern Med"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1172\/JCI112088","volume":"76","author":"Chabner B.A.","year":"1985","unstructured":"Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, Drake JC, Jolivet J. Polyglutamation of methotrexate. Is methotrexate a prodrug?","journal-title":"J Clin Invest"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2174\/138920012800840400","volume":"13","author":"de Beaumais T.A.","year":"2012","unstructured":"de Beaumais TA, Jacqz-Aigrain E. Intracellular disposition of methotrexate in acute lymphoblastic leukemia in children.","journal-title":"Curr Drug Metab"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1016\/0006-2952(79)90039-X","volume":"28","author":"Szeto D.W.","year":"1979","unstructured":"Szeto DW, Cheng YC, Rosowsky A, Yu CS, Modest EJ, Piper JR, Temple C, Elliott RD, Rose JD, Montgomery JA. Human thymidylate synthetase--iii. Effects of methotrexate and folate analogs.","journal-title":"Biochem Pharmacol"},{"key":"ref=16","first-page":"105","volume":"17","author":"Galivan J.","year":"1980","unstructured":"Galivan J. Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate.","journal-title":"Mol Pharmacol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1073\/pnas.82.15.4881","volume":"82","author":"Allegra C.J.","year":"1985","unstructured":"Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/ng0595-111","volume":"10","author":"Frosst P.","year":"1995","unstructured":"Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, Boers GJ, Den Heijer M, Kluijtmans LA, Van Den Heuvel LP. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase.","journal-title":"Nat Genet"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1086\/301825","volume":"62","author":"Van Der Put N.M.","year":"1998","unstructured":"Van Der Put NM, Gabreels F, Stevens EM, Smeitink JA, Trijbels FJ, Eskes TK, Van Den Heuvel LP, Blom HJ. A second common mutation in the methylenetetrahydrofolate reductase gene: An additional risk factor for neural-tube defects?","journal-title":"Am J Hum Genet"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nrc1800","volume":"6","author":"Cheok M.H.","year":"2006","unstructured":"Cheok MH, Evans WE. Acute lymphoblastic leukaemia: A model for the pharmacogenomics of cancer therapy.","journal-title":"Nat Rev Cancer"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0021-9150(98)00154-3","volume":"141","author":"Brattstrom L.","year":"1998","unstructured":"Brattstrom L, Zhang Y, Hurtig M, Refsum H, Ostensson S, Fransson L, Jones K, Landgren F, Brudin L, Ueland PM. A common methylenetetrahydrofolate reductase gene mutation and longevity.","journal-title":"Atherosclerosis"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1006\/mgme.1998.2714","volume":"64","author":"Weisberg I.","year":"1998","unstructured":"Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. A second genetic polymorphism in methylenetetrahydrofolate reductase (mthfr) associated with decreased enzyme activity.","journal-title":"Mol Genet Metab"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1007\/s12032-011-9997-6","volume":"29","author":"El-Khodary N.M.","year":"2012","unstructured":"El-Khodary NM, El-Haggar SM, Eid MA, Ebeid EN. Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia.","journal-title":"Med Oncol"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1007\/s00280-011-1665-1","volume":"68","author":"D\u2019Angelo V.","year":"2011","unstructured":"D\u2019Angelo V, Ramaglia M, Iannotta A, Crisci S, Indolfi P, Francese M, Affinita MC, Pecoraro G, Napolitano A, Fusco C, Oreste M, Indolfi C, Casale F. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and mthfr polymorphisms as pharmacogenetic determinants.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3109\/10428194.2014.951844","volume":"56","author":"Araoz H.V.","year":"2015","unstructured":"Araoz HV, D\u2019Aloi K, Foncuberta ME, Sanchez La Rosa CG, Alonso CN, Chertkoff L, Felice M. Pharmacogenetic studies in children with acute lymphoblastic leukemia in argentina.","journal-title":"Leuk Lymphoma"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/gtmb.2010.0083","volume":"15","author":"Karathanasis N.V.","year":"2011","unstructured":"Karathanasis NV, Stiakaki E, Goulielmos GN, Kalmanti M. The role of the methylenetetrahydrofolate reductase 677 and 1298 polymorphisms in cretan children with acute lymphoblastic leukemia.","journal-title":"Genet Test Mol Biomarkers"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.17219\/acem\/69802","volume":"27","author":"Mahmoud L.B.","year":"2018","unstructured":"Mahmoud LB, Mdhaffar M, Frikha R, Ghozzi H, Hakim A, Sahnoun Z, Elloumi M, Zeghal K. Use of mthfr c677t polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.","journal-title":"Adv Clin Exp Med"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/pbc.21815","volume":"52","author":"Pietrzyk J.J.","year":"2009","unstructured":"Pietrzyk JJ, Bik-Multanowski M, Balwierz W, Skoczen S, Wojcik D, Chybicka A, Sikorska-Fic B, Matysiak M, Szczepanski T, Sonta-Jakimczyk D, Ploszynska A, Balcerska A, Mycko K, Bodalski J, Krawczuk-Rybak M, Kowalczyk J, Koltan A, Sobol G, Derwich K, Kwinta P. Additional genetic risk factor for death in children with acute lymphoblastic leukemia: A common polymorphism of the mthfr gene.","journal-title":"Pediatr Blood Cancer"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1089\/gtmb.2015.0287","volume":"20","author":"Ramirez-Pacheco A.","year":"2016","unstructured":"Ramirez-Pacheco A, Moreno-Guerrero S, Alamillo I, Medina-Sanson A, Lopez B, Moreno-Galvan M. Mexican childhood acute lymphoblastic leukemia: A pilot study of the mdr1 and mthfr gene polymorphisms and their associations with clinical outcomes.","journal-title":"Genet Test Mol Biomarkers"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/MPH.0b013e318165b25d","volume":"30","author":"Shimasaki N.","year":"2008","unstructured":"Shimasaki N, Mori T, Torii C, Sato R, Shimada H, Tanigawara Y, Kosaki K, Takahashi T. Influence of mthfr and rfc1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma.","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.3109\/10428194.2013.825902","volume":"55","author":"Tanaka Y.","year":"2014","unstructured":"Tanaka Y, Manabe A, Nakadate H, Kondoh K, Nakamura K, Koh K, Kikuchi A, Komiyama T. Methylenetetrahydrofolate reductase gene haplotypes affect toxicity during maintenance therapy for childhood acute lymphoblastic leukemia in Japanese patients.","journal-title":"Leuk Lymphoma"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/FPC.0000000000000069","volume":"24","author":"Zgheib N.K.","year":"2014","unstructured":"Zgheib NK, Akra-Ismail M, Aridi C, Mahfouz R, Abboud MR, Solh H, Muwakkit SA. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in lebanese children with acute lymphoblastic leukemia.","journal-title":"Pharmacogenet Genomics"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ajh.21897","volume":"86","author":"Vagace J.M.","year":"2011","unstructured":"Vagace JM, Caceres-Marzal C, Jimenez M, Casado MS, de Murillo SG, Gervasini G. Methotrexate-induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis.","journal-title":"Am J Hematol"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3109\/08880010903341904","volume":"27","author":"Mahadeo K.M.","year":"2010","unstructured":"Mahadeo KM, Dhall G, Panigrahy A, Lastra C, Ettinger LJ. Subacute methotrexate neurotoxicity and cerebral venous sinus thrombosis in a 12-year-old with acute lymphoblastic leukemia and methylenetetrahydrofolate reductase (mthfr) c677t polymorphism: Homocysteine-mediated methotrexate neurotoxicity direct endothelial injury.","journal-title":"Pediatr Hematol Oncol"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/mpo.10192","volume":"40","author":"Strunk T.","year":"2003","unstructured":"Strunk T, Gottschalk S, Goepel W, Bucsky P, Schultz C. Subacute leukencephalopathy after low-dose intrathecal methotrexate in an adolescent heterozygous for the mthfr c677t polymorphism.","journal-title":"Med Pediatr Oncol"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1200\/JCO.2003.07.056","volume":"21","author":"Kishi S.","year":"2003","unstructured":"Kishi S, Griener J, Cheng C, Das S, Cook EH, Pei D, Hudson M, Rubnitz J, Sandlund JT, Pui CH, Relling MV. Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia.","journal-title":"J Clin Oncol"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1365-2141.2004.04932.x","volume":"125","author":"Aplenc R.","year":"2004","unstructured":"Aplenc R, Lange B. Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia.","journal-title":"Br J Haematol"},{"key":"ref=38","first-page":"292043","volume":"2012","author":"De Deus D.M.","year":"2012","unstructured":"De Deus DM, De Lima EL, Seabra Silva RM, Leite EP, Cartaxo Muniz MT. Influence of methylenetetrahydrofolate reductase c677t, a1298c, and g80a polymorphisms on the survival of pediatric patients with acute lymphoblastic leukemia.","journal-title":"Leukemia Res Treat"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.3109\/10428194.2011.639880","volume":"53","author":"Erculj N.","year":"2012","unstructured":"Erculj N, Kotnik BF, Debeljak M, Jazbec J, Dolzan V. Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia.","journal-title":"Leuk Lymphoma"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1038\/leu.2008.66","volume":"22","author":"Huang L.","year":"2008","unstructured":"Huang L, Tissing WJ, de Jonge R, van Zelst BD, Pieters R. Polymorphisms in folate-related genes: Association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia.","journal-title":"Leukemia"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"e45558","DOI":"10.1371\/journal.pone.0045558","volume":"7","author":"Kim H.","year":"2012","unstructured":"Kim H, Kang HJ, Kim HJ, Jang MK, Kim NH, Oh Y, Han BD, Choi JY, Kim CW, Lee JW, Park KD, Shin HY, Ahn HS. Pharmacogenetic analysis of pediatric patients with acute lymphoblastic leukemia: A possible association between survival rate and itpa polymorphism.","journal-title":"PLoS One"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1007\/s00280-011-1719-4","volume":"68","author":"Lopez-Lopez E.","year":"2011","unstructured":"Lopez-Lopez E, Ballesteros J, Garcia-Orad A. Mthfr 677tt genotype and toxicity of methotrexate: Controversial results.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"85","DOI":"10.4103\/0971-5851.180144","volume":"37","author":"Moulik N.R.","year":"2016","unstructured":"Moulik NR, Kumar A, Agrawal S, Mahdi AA. Effect of folate status and methylenetetrahydrofolate reductase genotypes on the complications and outcome of high dose methotrexate chemotherapy in north indian children with acute lymphoblastic leukemia.","journal-title":"Indian J Med Paediatr Oncol"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"5145","DOI":"10.1182\/blood-2013-01-480335","volume":"121","author":"Radtke S.","year":"2013","unstructured":"Radtke S, Zolk O, Renner B, Paulides M, Zimmermann M, Moricke A, Stanulla M, Schrappe M, Langer T. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia.","journal-title":"Blood"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/01.mph.0000198269.61948.90","volume":"28","author":"Shimasaki N.","year":"2006","unstructured":"Shimasaki N, Mori T, Samejima H, Sato R, Shimada H, Yahagi N, Torii C, Yoshihara H, Tanigawara Y, Takahashi T, Kosaki K. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma.","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/ped.12682","volume":"57","author":"Suzuki R.","year":"2015","unstructured":"Suzuki R, Fukushima H, Noguchi E, Tsuchida M, Kiyokawa N, Koike K, Ma E, Takahashi H, Kobayashi C, Nakajima-Yamaguchi R, Sakai A, Saito M, Iwabuchi A, Kato K, Nakao T, Yoshimi A, Sumazaki R, Fukushima T. Influence of slco1b1 polymorphism on maintenance therapy for childhood leukemia.","journal-title":"Pediatr Int"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1002\/pbc.26090","volume":"63","author":"Tsujimoto S.","year":"2016","unstructured":"Tsujimoto S, Yanagimachi M, Tanoshima R, Urayama KY, Tanaka F, Aida N, Goto H, Ito S. Influence of adora2a gene polymorphism on leukoencephalopathy risk in mtx-treated pediatric patients affected by hematological malignancies.","journal-title":"Pediatr Blood Cancer"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s00280-014-2507-8","volume":"74","author":"Wang S.M.","year":"2014","unstructured":"Wang SM, Sun LL, Zeng WX, Wu WS, Zhang GL. Influence of genetic polymorphisms of fpgs, ggh, and mthfr on serum methotrexate levels in chinese children with acute lymphoblastic leukemia.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4274\/tjh.2016.0007","volume":"34","author":"Yazicioglu B.","year":"2017","unstructured":"Yazicioglu B, Kaya Z, Guntekin Ergun S, Percin F, Kocak U, Yenicesu I, Gursel T. Influence of folate-related gene polymorphisms on high-dose methotrexate-related toxicity and prognosis in turkish children with acute lymphoblastic leukemia.","journal-title":"Turk J Haematol"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1158\/0008-5472.CAN-04-2606","volume":"65","author":"Aplenc R.","year":"2005","unstructured":"Aplenc R, Thompson J, Han P, La M, Zhao H, Lange B, Rebbeck T. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia.","journal-title":"Cancer Res"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/10428190902893819","volume":"50","author":"Kantar M.","year":"2009","unstructured":"Kantar M, Kosova B, Cetingul N, Gumus S, Toroslu E, Zafer N, Topcuoglu N, Aksoylar S, Cinar M, Tetik A, Eroglu Z. Methylenetetrahydrofolate reductase c677t and a1298c gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-hodgkin lymphoma.","journal-title":"Leuk Lymphoma"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1055\/s-0032-1304623","volume":"224","author":"Haase R.","year":"2012","unstructured":"Haase R, Elsner K, Merkel N, Stiefel M, Mauz-Korholz C, Kramm CM, Korholz D. High dose methotrexate treatment in childhood all: Pilot study on the impact of the mthfr 677c>t and 1298a>c polymorphisms on mtx-related toxicity.","journal-title":"Klin Padiatr"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.3109\/10428194.2014.947608","volume":"56","author":"Roy Moulik N.","year":"2015","unstructured":"Roy Moulik N, Kumar A, Agrawal S, Awasthi S, Mahdi AA. Role of folate status and methylenetetrahydrofolate reductase genotype on the toxicity and outcome of induction chemotherapy in children with acute lymphoblastic leukemia.","journal-title":"Leuk Lymphoma"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/pbc.23162","volume":"57","author":"Kamdar K.Y.","year":"2011","unstructured":"Kamdar KY, Krull KR, El-Zein RA, Brouwers P, Potter BS, Harris LL, Holm S, Dreyer Z, Scaglia F, Etzel CJ, Bondy M, Okcu MF. Folate pathway polymorphisms predict deficits in attention and processing speed after childhood leukemia therapy.","journal-title":"Pediatr Blood Cancer"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1007\/s00228-011-1046-z","volume":"67","author":"Faganel Kotnik B.","year":"2011","unstructured":"Faganel Kotnik B, Grabnar I, Bohanec Grabar P, Dolzan V, Jazbec J. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/tpj.2012.44","volume":"13","author":"Lopez-Lopez E.","year":"2013","unstructured":"Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Garcia-Orad A. A systematic review and meta-analysis of mthfr polymorphisms in methotrexate toxicity prediction in pediatric acute lymphoblastic leukemia.","journal-title":"Pharmacogenomics J"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/10245332.2018.1500750","volume":"24","author":"Yao P.","year":"2018","unstructured":"Yao P, He X, Zhang R, Tong R, Xiao H. The influence of mthfr genetic polymorphisms on adverse reactions after methotrexate in patients with hematological malignancies: A meta-analysis.","journal-title":"Hematology"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s13277-012-0395-2","volume":"33","author":"Yang L.","year":"2012","unstructured":"Yang L, Hu X, Xu L. Impact of methylenetetrahydrofolate reductase (mthfr) polymorphisms on methotrexate-induced toxicities in acute lymphoblastic leukemia: A meta-analysis.","journal-title":"Tumour Biol"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/sj.tpj.6500224","volume":"4","author":"Krajinovic M.","year":"2004","unstructured":"Krajinovic M, Lemieux-Blanchard E, Chiasson S, Primeau M, Costea I, Moghrabi A. Role of polymorphisms in mthfr and mthfd1 genes in the outcome of childhood acute lymphoblastic leukemia.","journal-title":"Pharmacogenomics J"},{"key":"ref=60","first-page":"238528","volume":"2013","author":"Fukushima H.","year":"2013","unstructured":"Fukushima H, Fukushima T, Sakai A, Suzuki R, Nakajima-Yamaguchi R, Kobayashi C, Iwabuchi A, Saito M, Yoshimi A, Nakao T, Kato K, Tsuchida M, Takahashi H, Koike K, Kiyokawa N, Noguchi E, Sumazaki R. Polymorphisms of mthfr associated with higher relapse\/death ratio and delayed weekly mtx administration in pediatric lymphoid malignancies.","journal-title":"Leukemia Res Treat"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"110","DOI":"10.18632\/oncotarget.8606","volume":"8","author":"Leonardi D.B.","year":"2017","unstructured":"Leonardi DB, Abbate M, Riccheri MC, Nunez M, Alfonso G, Gueron G, De Siervi A, Vazquez E, Cotignola J. Improving risk stratification of patients with childhood acute lymphoblastic leukemia: Glutathione-s-transferases polymorphisms are associated with increased risk of relapse.","journal-title":"Oncotarget"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bcp.12481","volume":"79","author":"Hoang P.T.","year":"2015","unstructured":"Hoang PT, Ambroise J, Dekairelle AF, Durant JF, Butoescu V, Chi VL, Huynh N, Nguyen TB, Robert A, Vermylen C, Gala JL. Comparative pharmacogenetic analysis of risk polymorphisms in caucasian and vietnamese children with acute lymphoblastic leukemia: Prediction of therapeutic outcome?","journal-title":"Br J Clin Pharmacol"},{"key":"ref=63","first-page":"154","volume":"68","author":"Candelaria M.","year":"2016","unstructured":"Candelaria M, Ojeda J, Gutierrez-Hernandez O, Taja-Chayeb L, Vidal-Millan S, Duenas-Gonzalez A. G80a single nucleotide polymorphism in reduced folate carrier-1 gene in a mexican population and its impact on survival in patients with acute lymphoblastic leukemia.","journal-title":"Rev Invest Clin"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/tpj.2014.10","volume":"14","author":"He H.R.","year":"2014","unstructured":"He HR, Chen SY, You HS, Hu SS, Sun JY, Dong YL, Lu J. Association between methylenetetrahydrofolate reductase polymorphisms and the relapse of acute lymphoblastic leukemia: A meta-analysis.","journal-title":"Pharmacogenomics J"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/10428194.2013.792336","volume":"55","author":"Ojha R.P.","year":"2014","unstructured":"Ojha RP, Gurney JG. Methylenetetrahydrofolate reductase c677t and overall survival in pediatric acute lymphoblastic leukemia: A systematic review.","journal-title":"Leuk Lymphoma"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/tpj.2011.25","volume":"12","author":"Salazar J.","year":"2012","unstructured":"Salazar J, Altes A, del Rio E, Estella J, Rives S, Tasso M, Navajas A, Molina J, Villa M, Vivanco JL, Torrent M, Baiget M, Badell I. Methotrexate consolidation treatment according to pharmacogenetics of mthfr ameliorates event-free survival in childhood acute lymphoblastic leukaemia.","journal-title":"Pharmacogenomics J"},{"key":"ref=67","first-page":"2538","volume":"6","author":"Welsh S.J.","year":"2000","unstructured":"Welsh SJ, Titley J, Brunton L, Valenti M, Monaghan P, Jackman AL, Aherne GW. Comparison of thymidylate synthase (ts) protein up-regulation after exposure to ts inhibitors in normal and tumor cell lines and tissues.","journal-title":"Clin Cancer Res"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1247\/csf.20.191","volume":"20","author":"Horie N.","year":"1995","unstructured":"Horie N, Aiba H, Oguro K, Hojo H, Takeishi K. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5\u2032-terminal regulatory region of the human gene for thymidylate synthase.","journal-title":"Cell Struct Funct"},{"key":"ref=69","first-page":"5505","volume":"61","author":"Wang W.","year":"2001","unstructured":"Wang W, Marsh S, Cassidy J, McLeod HL. Pharmacogenomic dissection of resistance to thymidylate synthase inhibitors.","journal-title":"Cancer Res"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"26393","DOI":"10.1002\/pbc.26393","volume":"64","author":"Finkelstein Y.","year":"2017","unstructured":"Finkelstein Y, Blonquist TM, Vijayanathan V, Stevenson KE, Neuberg DS, Silverman LB, Vrooman LM, Sallan SE, Cole PD. A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia.","journal-title":"Pediatr Blood Cancer"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood-2004-12-4941","volume":"106","author":"De Jonge R.","year":"2005","unstructured":"De Jonge R, Hooijberg JH, van Zelst BD, Jansen G, Van Zantwijk CH, Kaspers GJ, Peters GJ, Ravindranath Y, Pieters R, Lindemans J. Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia.","journal-title":"Blood"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s00277-007-0274-x","volume":"86","author":"Pakakasama S.","year":"2007","unstructured":"Pakakasama S, Kanchanakamhaeng K, Kajanachumpol S, Udomsubpayakul U, Sirachainan N, Thithapandha A, Hongeng S. Genetic polymorphisms of folate metabolic enzymes and toxicities of high dose methotrexate in children with acute lymphoblastic leukemia.","journal-title":"Ann Hematol"},{"key":"ref=73","first-page":"2898","volume":"63","author":"Mandola M.V.","year":"2003","unstructured":"Mandola MV, Stoehlmacher J, Muller-Weeks S, Cesarone G, Yu MC, Lenz HJ, Ladner RD. A novel single nucleotide polymorphism within the 5\u2032 tandem repeat polymorphism of the thymidylate synthase gene abolishes usf-1 binding and alters transcriptional activity.","journal-title":"Cancer Res"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/FPC.0000000000000352","volume":"28","author":"Oosterom N.","year":"2018","unstructured":"Oosterom N, Berrevoets M, Den Hoed MAH, Zolk O, Hoerning S, Pluijm SMF, Pieters R, De Jonge R, Tissing WJE, Van Den Heuvel-Eibrink MM, Heil SG. The role of genetic polymorphisms in the thymidylate synthase (tyms) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia.","journal-title":"Pharmacogenet Genomics"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.leukres.2011.04.007","volume":"35","author":"Pietrzyk J.J.","year":"2011","unstructured":"Pietrzyk JJ, Bik-Multanowski M, Skoczen S, Kowalczyk J, Balwierz W. AlicjaChybicka; Matysiak, M.; Szczepanski, T.; Balcerska, A.; Bodalski, J.; Krawczuk-Rybak, M.; Wysocki, M.; Sobol, G.; Wachowiak, J. Polymorphism of the thymidylate synthase gene and risk of relapse in childhood all.","journal-title":"Leuk Res"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.leukres.2008.12.006","volume":"33","author":"Da Silva Silveira V.","year":"2009","unstructured":"Da Silva Silveira V, Canalle R, Scrideli CA, Queiroz RG, Bettiol H, Valera ET, Tone LG. Polymorphisms of xenobiotic metabolizing enzymes and DNA repair genes and outcome in childhood acute lymphoblastic leukemia.","journal-title":"Leuk Res"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(02)08065-0","volume":"359","author":"Krajinovic M.","year":"2002","unstructured":"Krajinovic M, Costea I, Chiasson S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia.","journal-title":"Lancet"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/sj.tpj.6500332","volume":"5","author":"Krajinovic M.","year":"2005","unstructured":"Krajinovic M, Costea I, Primeau M, Dulucq S, Moghrabi A. Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis.","journal-title":"Pharmacogenomics J"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/00008571-200309000-00006","volume":"13","author":"Costea I.","year":"2003","unstructured":"Costea I, Moghrabi A, Krajinovic M. The influence of cyclin d1 (ccnd1) 870a>g polymorphism and ccnd1-thymidylate synthase (ts) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia.","journal-title":"Pharmacogenetics"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"10436","DOI":"10.1073\/pnas.92.22.10436","volume":"92","author":"Li W.","year":"1995","unstructured":"Li W, Fan J, Hochhauser D, Banerjee D, Zielinski Z, Almasan A, Yin Y, Kelly R, Wahl GM, Bertino JR. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.leukres.2007.03.028","volume":"31","author":"Chiusolo P.","year":"2007","unstructured":"Chiusolo P, Reddiconto G, Farina G, Mannocci A, Fiorini A, Palladino M, La Torre G, Fianchi L, Sora F, Laurenti L, Leone G, Sica S. Mthfr polymorphisms\u2019 influence on outcome and toxicity in acute lymphoblastic leukemia patients.","journal-title":"Leuk Res"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1182\/blood-2007-09-110593","volume":"111","author":"Dulucq S.","year":"2008","unstructured":"Dulucq S, St-Onge G, Gagne V, Ansari M, Sinnett D, Labuda D, Moghrabi A, Krajinovic M. DNA variants in the dihydrofolate reductase gene and outcome in childhood all.","journal-title":"Blood"},{"key":"ref=83","first-page":"353","volume":"88","author":"Lauten M.","year":"2003","unstructured":"Lauten M, Asgedom G, Welte K, Schrappe M, Stanulla M. Thymidylate synthase gene polymorphism and its association with relapse in childhood b-cell precursor acute lymphoblastic leukemia.","journal-title":"Haematologica"},{"key":"ref=84","first-page":"1381","volume":"9","author":"Ulrich C.M.","year":"2000","unstructured":"Ulrich CM, Bigler J, Velicer CM, Greene EA, Farin FM, Potter JD. Searching expressed sequence tag databases: Discovery and confirmation of a common polymorphism in the thymidylate synthase gene.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00008571-200405000-00007","volume":"14","author":"Mandola M.V.","year":"2004","unstructured":"Mandola MV, Stoehlmacher J, Zhang W, Groshen S, Yu MC, Iqbal S, Lenz HJ, Ladner RDA. 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral ts mrna levels.","journal-title":"Pharmacogenetics"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.ygeno.2006.01.001","volume":"87","author":"Sinnett D.","year":"2006","unstructured":"Sinnett D, Beaulieu P, Belanger H, Lefebvre JF, Langlois S, Theberge MC, Drouin S, Zotti C, Hudson TJ, Labuda D. Detection and characterization of DNA variants in the promoter regions of hundreds of human disease candidate genes.","journal-title":"Genomics"},{"key":"ref=87","doi-asserted-by":"crossref","first-page":"6931","DOI":"10.1158\/1078-0432.CCR-09-0641","volume":"15","author":"Al-Shakfa F.","year":"2009","unstructured":"Al-Shakfa F, Dulucq S, Brukner I, Milacic I, Ansari M, Beaulieu P, Moghrabi A, Laverdiere C, Sallan SE, Silverman LB, Neuberg D, Kutok JL, Sinnett D, Krajinovic M. DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia.","journal-title":"Clin Cancer Res"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2217\/pgs-2017-0153","volume":"19","author":"Ceppi F.","year":"2018","unstructured":"Ceppi F, Gagne V, Douyon L, Quintin CJ, Colombini A, Parasole R, Buldini B, Basso G, Conter V, Cazzaniga G, Krajinovic M. DNA variants in dhfr gene and response to treatment in children with childhood b all: Revisited in aieop-bfm protocol.","journal-title":"Pharmacogenomics"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s00228-015-1930-z","volume":"71","author":"Kodidela S.","year":"2015","unstructured":"Kodidela S, Pradhan SC, Dubashi B, Basu D. Influence of dihydrofolate reductase gene polymorphisms rs408626 (-317a>g) and rs442767 (-680c>a) on the outcome of methotrexate-based maintenance therapy in south indian patients with acute lymphoblastic leukemia.","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/MPH.0000000000000908","volume":"39","author":"Gervasini G.","year":"2017","unstructured":"Gervasini G, De Murillo SG, Jimenez M, De La Maya MD, Vagace JM. Dihydrofolate reductase genetic polymorphisms affect methotrexate dose requirements in pediatric patients with acute lymphoblastic leukemia on maintenance therapy.","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1074\/jbc.272.8.4729","volume":"272","author":"Girgis S.","year":"1997","unstructured":"Girgis S, Suh JR, Jolivet J, Stover PJ. 5-formyltetrahydro-folate regulates homocysteine remethylation in human neuroblastoma.","journal-title":"J Biol Chem"},{"key":"ref=92","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1006\/mgme.2001.3175","volume":"73","author":"Heil S.G.","year":"2001","unstructured":"Heil SG, Van Der Put NM, Waas ET, Den Heijer M, Trijbels FJ, Blom HJ. Is mutated serine hydroxymethyltransferase (shmt) involved in the etiology of neural tube defects?","journal-title":"Mol Genet Metab"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/pbc.23074","volume":"57","author":"Lopez-Lopez E.","year":"2011","unstructured":"Lopez-Lopez E, Martin-Guerrero I, Ballesteros J, Pinan MA, Garcia-Miguel P, Navajas A, Garcia-Orad A. Polymorphisms of the slco1b1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukemia.","journal-title":"Pediatr Blood Cancer"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1002\/art.22129","volume":"54","author":"Dervieux T.","year":"2006","unstructured":"Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis.","journal-title":"Arthritis Rheum"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1182\/blood.V99.10.3786","volume":"99","author":"Skibola C.F.","year":"2002","unstructured":"Skibola CF, Smith MT, Hubbard A, Shane B, Roberts AC, Law GR, Rollinson S, Roman E, Cartwright RA, Morgan GJ. Polymorphisms in the thymidylate synthase and serine hydroxymethyltransferase genes and risk of adult acute lymphocytic leukemia.","journal-title":"Blood"},{"key":"ref=96","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0083-6729(08)60397-0","volume":"45","author":"Shane B.","year":"1989","unstructured":"Shane B. Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism.","journal-title":"Vitam Horm"},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1399-0004.1998.tb02658.x","volume":"53","author":"Hol F.A.","year":"1998","unstructured":"Hol FA, Van Der Put NM, Geurds MP, Heil SG, Trijbels FJ, Hamel BC, Mariman EC, Blom HJ. Molecular genetic analysis of the gene encoding the trifunctional enzyme mthfd (methylenetetrahydrofolate-dehydrogenase, methenyltetrahydrofolate-cyclohydrolase, formyltetrahydrofolate synthetase) in patients with neural tube defects.","journal-title":"Clin Genet"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/humu.20830","volume":"30","author":"Christensen K.E.","year":"2009","unstructured":"Christensen KE, Rohlicek CV, Andelfinger GU, Michaud J, Bigras JL, Richter A, Mackenzie RE, Rozen R. The mthfd1 p.Arg653gln variant alters enzyme function and increases risk for congenital heart defects.","journal-title":"Hum Mutat"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"8082","DOI":"10.1021\/bi9705164","volume":"36","author":"Goulding C.W.","year":"1997","unstructured":"Goulding CW, Postigo D, Matthews RG. Cobalamin-dependent methionine synthase is a modular protein with distinct regions for binding homocysteine, methyltetrahydrofolate, cobalamin, and adenosylmethionine.","journal-title":"Biochemistry (Mosc)"},{"key":"ref=100","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1093\/hmg\/5.12.1867","volume":"5","author":"Leclerc D.","year":"1996","unstructured":"Leclerc D, Campeau E, Goyette P, Adjalla CE, Christensen B, Ross M, Eydoux P, Rosenblatt DS, Rozen R, Gravel RA. Human methionine synthase: Cdna cloning and identification of mutations in patients of the cblg complementation group of folate\/cobalamin disorders.","journal-title":"Hum Mol Genet"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.18632\/aging.101509","volume":"10","author":"Shao H.B.","year":"2018","unstructured":"Shao HB, Ren K, Gao SL, Zou JG, Mi YY, Zhang LF, Zuo L, Okada A, Yasui T. Human methionine synthase a2756g polymorphism increases susceptibility to prostate cancer.","journal-title":"Aging (Albany NY)"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/(SICI)1098-2272(199911)17:4<298::AID-GEPI5>3.0.CO;2-V","volume":"17","author":"Harmon D.L.","year":"1999","unstructured":"Harmon DL, Shields DC, Woodside JV, McMaster D, Yarnell JW, Young IS, Peng K, Shane B, Evans AE, Whitehead AS. Methionine synthase d919g polymorphism is a significant but modest determinant of circulating homocysteine concentrations.","journal-title":"Genet Epidemiol"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00011-018-1161-8","volume":"67","author":"Chaabane S.","year":"2018","unstructured":"Chaabane S, Messedi M, Akrout R, Ben Hamad M, Turki M, Marzouk S, Keskes L, Bahloul Z, Rebai A, Ayedi F, Maalej A. Association of hyperhomocysteinemia with genetic variants in key enzymes of homocysteine metabolism and methotrexate toxicity in rheumatoid arthritis patients.","journal-title":"Inflamm Res"},{"key":"ref=104","first-page":"1664","volume":"34","author":"Berkun Y.","year":"2007","unstructured":"Berkun Y, Abou Atta I, Rubinow A, Orbach H, Levartovsky D, Aamar S, Arbel O, Dresner-Pollak R, Friedman G, Ben-Yehuda A. 2756gg genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis.","journal-title":"J Rheumatol"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.3109\/10428194.2013.867490","volume":"55","author":"Li S.Y.","year":"2014","unstructured":"Li SY, Ye JY, Liang EY, Yang M. The protective role of mtr a2756g polymorphisms in childhood acute lymphoblastic leukemia remains inconclusive.","journal-title":"Leuk Lymphoma"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.3109\/10428194.2013.867492","volume":"55","author":"Fang D.H.","year":"2014","unstructured":"Fang DH, Ji Q, Fan CH, An Q, Li J. Methionine synthase reductase a66g polymorphism and leukemia risk: Evidence from published studies.","journal-title":"Leuk Lymphoma"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.3109\/10428194.2013.830304","volume":"55","author":"Xia J.","year":"2014","unstructured":"Xia J, Wang Y, Zhang H, Hu Y. Association between mtr a2756g polymorphism and childhood acute lymphoblastic leukemia: A meta-analysis.","journal-title":"Leuk Lymphoma"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1517\/14622416.6.3.293","volume":"6","author":"Krajinovic M.","year":"2005","unstructured":"Krajinovic M, Robaey P, Chiasson S, Lemieux-Blanchard E, Rouillard M, Primeau M, Bournissen FG, Moghrabi A. Polymorphisms of genes controlling homocysteine levels and iq score following the treatment for childhood all.","journal-title":"Pharmacogenomics"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1006\/mgme.1999.2879","volume":"67","author":"Wilson A.","year":"1999","unstructured":"Wilson A, Platt R, Wu Q, Leclerc D, Christensen B, Yang H, Gravel RA, Rozen R. A common variant in methionine synthase reductase combined with low cobalamin (vitamin b12) increases risk for spina bifida.","journal-title":"Mol Genet Metab"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0021-9150(00)00739-5","volume":"157","author":"Gaughan D.J.","year":"2001","unstructured":"Gaughan DJ, Kluijtmans LA, Barbaux S, McMaster D, Young IS, Yarnell JW, Evans A, Whitehead AS. The methionine synthase reductase (mtrr) a66g polymorphism is a novel genetic determinant of plasma homocysteine concentrations.","journal-title":"Atherosclerosis"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0021-9150(02)00204-6","volume":"166","author":"Jacques P.F.","year":"2003","unstructured":"Jacques PF, Bostom AG, Selhub J, Rich S, Ellison RC, Eckfeldt JH, Gravel RA, Rozen R. Effects of polymorphisms of methionine synthase and methionine synthase reductase on total plasma homocysteine in the nhlbi family heart study.","journal-title":"Atherosclerosis"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1515\/jtim-2017-0037","volume":"5","author":"Wang J.","year":"2017","unstructured":"Wang J, Ouyang N, Qu L, Lin T, Zhang X, Yu Y, Jiang C, Xie L, Wang L, Wang Z, Ren S, Chen S, Huang J, Liu F, Huang W, Qin X. Effect of mthfr a1298c and mtrr a66g genetic mutations on homocysteine levels in the chinese population: A systematic review and meta-analysis.","journal-title":"J Transl Int Med"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2141.2009.07898.x","volume":"148","author":"Koppen I.J.","year":"2010","unstructured":"Koppen IJ, Hermans FJ, Kaspers GJ. Folate related gene polymorphisms and susceptibility to develop childhood acute lymphoblastic leukaemia.","journal-title":"Br J Haematol"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3324\/haematol.2010.022095","volume":"95","author":"Vijayakrishnan J.","year":"2010","unstructured":"Vijayakrishnan J, Houlston RS. Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: A systematic review and meta-analysis.","journal-title":"Haematologica"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"30244","DOI":"10.1038\/srep30244","volume":"6","author":"Smid A.","year":"2016","unstructured":"Smid A, Karas-Kuzelicki N, Jazbec J, Mlinaric-Rascan I. Pacsin2 polymorphism is associated with thiopurine-induced hematological toxicity in children with acute lymphoblastic leukaemia undergoing maintenance therapy.","journal-title":"Sci Rep"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/pbc.23192","volume":"58","author":"Sepe D.M.","year":"2012","unstructured":"Sepe DM, McWilliams T, Chen J, Kershenbaum A, Zhao H, La M, Devidas M, Lange B, Rebbeck TR, Aplenc R. Germline genetic variation and treatment response on ccg-1891.","journal-title":"Pediatr Blood Cancer"},{"key":"ref=117","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/leu.2009.282","volume":"24","author":"Leclerc G.J.","year":"2010","unstructured":"Leclerc GJ, Mou C, Leclerc GM, Mian AM, Barredo JC. Histone deacetylase inhibitors induce fpgs mrna expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: Implications for combination therapy.","journal-title":"Leukemia"},{"key":"ref=118","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1038\/sj.leu.2401943","volume":"14","author":"Rots M.G.","year":"2000","unstructured":"Rots MG, Willey JC, Jansen G, Van Zantwijk CH, Noordhuis P, DeMuth JP, Kuiper E, Veerman AJ, Pieters R, Peters GJ. Mrna expression levels of methotrexate resistance-related proteins in childhood leukemia as determined by a standardized competitive template-based rt-pcr method.","journal-title":"Leukemia"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"8772","DOI":"10.1158\/0008-5472.CAN-07-0156","volume":"67","author":"Leil T.A.","year":"2007","unstructured":"Leil TA, Endo C, Adjei AA, Dy GK, Salavaggione OE, Reid JR, Ames MM. Identification and characterization of genetic variation in the folylpolyglutamate synthase gene.","journal-title":"Cancer Res"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"4967","DOI":"10.12659\/MSM.899021","volume":"22","author":"Huang Z.","year":"2016","unstructured":"Huang Z, Tong HF, Li Y, Qian JC, Wang JX, Wang Z, Ruan JC. Effect of the polymorphism of folylpolyglutamate synthetase on treatment of high-dose methotrexate in pediatric patients with acute lymphocytic leukemia.","journal-title":"Med Sci Monit"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3892\/ol.2014.2175","volume":"8","author":"Gomez-Gomez Y.","year":"2014","unstructured":"Gomez-Gomez Y, Organista-Nava J, Rangel-Rodriguez CA, Illades-Aguiar B, Moreno-Godinez ME, Alarcon-Romero LD, Leyva-Vazquez MA. Effect of folylpolyglutamate synthase a22g polymorphism on the risk and survival of patients with acute lymphoblastic leukemia.","journal-title":"Oncol Lett"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1182\/blood-2008-08-173799","volume":"113","author":"Stark M.","year":"2009","unstructured":"Stark M, Wichman C, Avivi I, Assaraf YG. Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia.","journal-title":"Blood"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1002\/ijc.29919","volume":"138","author":"Wojtuszkiewicz A.","year":"2016","unstructured":"Wojtuszkiewicz A, Raz S, Stark M, Assaraf YG, Jansen G, Peters GJ, Sonneveld E, Kaspers GJ, Cloos J. Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance.","journal-title":"Int J Cancer"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/01.fpc.0000114761.78957.7e","volume":"14","author":"Cheng Q.","year":"2004","unstructured":"Cheng Q, Wu B, Kager L, Panetta JC, Zheng J, Pui CH, Relling MV, Evans WE. A substrate specific functional polymorphism of human gamma-glutamyl hydrolase alters catalytic activity and methotrexate polyglutamate accumulation in acute lymphoblastic leukaemia cells.","journal-title":"Pharmacogenetics"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0378-1119(03)00807-2","volume":"319","author":"Chave K.J.","year":"2003","unstructured":"Chave KJ, Ryan TJ, Chmura SE, Galivan J. Identification of single nucleotide polymorphisms in the human gamma-glutamyl hydrolase gene and characterization of promoter polymorphisms.","journal-title":"Gene"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.7314\/APJCP.2012.13.7.3461","volume":"13","author":"Koomdee N.","year":"2012","unstructured":"Koomdee N, Hongeng S, Apibal S, Pakakasama S. Association between polymorphisms of dihydrofolate reductase and gamma glutamyl hydrolase genes and toxicity of high dose methotrexate in children with acute lymphoblastic leukemia.","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.leukres.2006.08.007","volume":"31","author":"Garcia-Bournissen F.","year":"2007","unstructured":"Garcia-Bournissen F, Moghrabi A, Krajinovic M. Therapeutic responses in childhood acute lymphoblastic leukemia (all) and haplotypes of gamma glutamyl hydrolase (ggh) gene.","journal-title":"Leuk Res"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1124\/pr.110.002857","volume":"63","author":"Niemi M.","year":"2011","unstructured":"Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1b1: A genetically polymorphic transporter of major importance for hepatic drug uptake.","journal-title":"Pharmacol Rev"},{"key":"ref=129","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1158\/1078-0432.CCR-06-2145","volume":"13","author":"Ge Y.","year":"2007","unstructured":"Ge Y, Haska CL, LaFiura K, Devidas M, Linda SB, Liu M, Thomas R, Taub JW, Matherly LH. Prognostic role of the reduced folate carrier, the major membrane transporter for methotrexate, in childhood acute lymphoblastic leukemia: A report from the children\u2019s oncology group.","journal-title":"Clin Cancer Res"},{"key":"ref=130","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1006\/mgme.2000.3034","volume":"70","author":"Chango A.","year":"2000","unstructured":"Chango A, Emery-Fillon N, de Courcy GP, Lambert D, Pfister M, Rosenblatt DS, Nicolas JP. A polymorphism (80g->a) in the reduced folate carrier gene and its associations with folate status and homocysteinemia.","journal-title":"Mol Genet Metab"},{"key":"ref=131","first-page":"3416","volume":"7","author":"Whetstine J.R.","year":"2001","unstructured":"Whetstine JR, Gifford AJ, Witt T, Liu XY, Flatley RM, Norris M, Haber M, Taub JW, Ravindranath Y, Matherly LH. Single nucleotide polymorphisms in the human reduced folate carrier: Characterization of a high-frequency g\/a variant at position 80 and transport properties of the his(27) and arg(27) carriers.","journal-title":"Clin Cancer Res"},{"key":"ref=132","doi-asserted-by":"crossref","first-page":"37761","DOI":"10.18632\/oncotarget.17781","volume":"8","author":"Liu S.G.","year":"2017","unstructured":"Liu SG, Gao C, Zhang RD, Zhao XX, Cui L, Li WJ, Chen ZP, Yue ZX, Zhang YY, Wu MY, Wang JX, Li ZG, Zheng HY. Polymorphisms in methotrexate transporters and their relationship to plasma methotrexate levels, toxicity of high-dose methotrexate, and outcome of pediatric acute lymphoblastic leukemia.","journal-title":"Oncotarget"},{"key":"ref=133","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/blood.V100.10.3832","volume":"100","author":"Laverdiere C.","year":"2002","unstructured":"Laverdiere C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism g80a in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia.","journal-title":"Blood"},{"key":"ref=134","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1182\/blood-2010-01-256958","volume":"115","author":"Gregers J.","year":"2010","unstructured":"Gregers J, Christensen IJ, Dalhoff K, Lausen B, Schroeder H, Rosthoej S, Carlsen N, Schmiegelow K, Peterson C. The association of reduced folate carrier 80g>a polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number.","journal-title":"Blood"},{"key":"ref=135","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s10038-006-0096-z","volume":"52","author":"Imanishi H.","year":"2007","unstructured":"Imanishi H, Okamura N, Yagi M, Noro Y, Moriya Y, Nakamura T, Hayakawa A, Takeshima Y, Sakaeda T, Matsuo M, Okumura K. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma.","journal-title":"J Hum Genet"},{"key":"ref=136","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1182\/blood-2006-10-054528","volume":"109","author":"Kishi S.","year":"2007","unstructured":"Kishi S, Cheng C, French D, Pei D, Das S, Cook EH, Hijiya N, Rizzari C, Rosner GL, Frudakis T, Pui CH, Evans WE, Relling MV. Ancestry and pharmacogenetics of antileukemic drug toxicity.","journal-title":"Blood"},{"key":"ref=137","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.3109\/10428194.2014.898761","volume":"55","author":"He H.R.","year":"2014","unstructured":"He HR, Liu P, He GH, Dong WH, Wang MY, Dong YL, Lu J. Association between reduced folate carrier g80a polymorphism and methotrexate toxicity in childhood acute lymphoblastic leukemia: A meta-analysis.","journal-title":"Leuk Lymphoma"},{"key":"ref=138","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/ijlh.12160","volume":"36","author":"Karathanasis N.V.","year":"2014","unstructured":"Karathanasis NV, Stiakaki E, Goulielmos G, Kalmanti M. The effect of rfc g80a polymorphism in cretan children with acute lymphoblastic leukemia and its interaction with mthfr c677t and a1298c polymorphisms.","journal-title":"Int J Lab Hematol"},{"key":"ref=139","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1182\/blood-2004-11-4544","volume":"105","author":"Rocha J.C.","year":"2005","unstructured":"Rocha JC, Cheng C, Liu W, Kishi S, Das S, Cook EH, Sandlund JT, Rubnitz J, Ribeiro R, Campana D, Pui CH, Evans WE, Relling MV. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia.","journal-title":"Blood"},{"key":"ref=140","doi-asserted-by":"crossref","first-page":"29427","DOI":"10.1038\/srep29427","volume":"6","author":"Dawidowska M.","year":"2016","unstructured":"Dawidowska M, Kosmalska M, Sedek L, Szczepankiewicz A, Twardoch M, Sonsala A, Szarzynska-Zawadzka B, Derwich K, Lejman M, Pawelec K, Obitko-Pludowska A, Pawinska-Wasikowska K, Kwiecinska K, Koltan A, Dyla A, Grzeszczak W, Kowalczyk JR, Szczepanski T, Zietkiewicz E, Witt M. Association of germline genetic variants in rfc, il15 and vdr genes with minimal residual disease in pediatric b-cell precursor all.","journal-title":"Sci Rep"},{"key":"ref=141","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s11999-008-0323-3","volume":"466","author":"Yang R.","year":"2008","unstructured":"Yang R, Qin J, Hoang BH, Healey JH, Gorlick R. Polymorphisms and methylation of the reduced folate carrier in osteosarcoma.","journal-title":"Clin Orthop Relat Res"},{"key":"ref=142","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00296-007-0339-0","volume":"27","author":"Chatzikyriakidou A.","year":"2007","unstructured":"Chatzikyriakidou A, Georgiou I, Voulgari PV, Papadopoulos CG, Tzavaras T, Drosos AA. Transcription regulatory polymorphism -43t>c in the 5\u2032-flanking region of slc19a1 gene could affect rheumatoid arthritis patient response to methotrexate therapy.","journal-title":"Rheumatol Int"},{"key":"ref=143","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1053\/gast.2001.24804","volume":"120","author":"Abe T.","year":"2001","unstructured":"Abe T, Unno M, Onogawa T, Tokui T, Kondo TN, Nakagomi R, Adachi H, Fujiwara K, Okabe M, Suzuki T, Nunoki K, Sato E, Kakyo M, Nishio T, Sugita J, Asano N, Tanemoto M, Seki M, Date F, Ono K, Kondo Y, Shiiba K, Suzuki M, Ohtani H, Shimosegawa T, Iinuma K, Nagura H, Ito S, Matsuno S. Lst-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers.","journal-title":"Gastroenterology"},{"key":"ref=144","doi-asserted-by":"crossref","first-page":"35669","DOI":"10.1074\/jbc.M103792200","volume":"276","author":"Tirona R.G.","year":"2001","unstructured":"Tirona RG, Leake BF, Merino G, Kim RB. Polymorphisms in oatp-c: Identification of multiple allelic variants associated with altered transport activity among european- and african-americans.","journal-title":"J Biol Chem"},{"key":"ref=145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gr.129668.111","volume":"22","author":"Ramsey L.B.","year":"2012","unstructured":"Ramsey LB, Bruun GH, Yang W, Trevino LR, Vattathil S, Scheet P, Cheng C, Rosner GL, Giacomini KM, Fan Y, Sparreboom A, Mikkelsen TS, Corydon TJ, Pui CH, Evans WE, Relling MV. Rare common variants in pharmacogenetics: Slco1b1 variation and methotrexate disposition.","journal-title":"Genome Res"},{"key":"ref=146","first-page":"6109","volume":"8","author":"Li J.","year":"2015","unstructured":"Li J, Wang XR, Zhai XW, Wang HS, Qian XW, Miao H, Zhu XH. Association of slco1b1 gene polymorphisms with toxicity response of high dose methotrexate chemotherapy in childhood acute lymphoblastic leukemia.","journal-title":"Int J Clin Exp Med"},{"key":"ref=147","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/pbc.25191","volume":"61","author":"Zhang H.N.","year":"2014","unstructured":"Zhang HN, He XL, Wang C, Wang Y, Chen YJ, Li JX, Niu CH, Gao P. Impact of slco1b1 521t > c variant on leucovorin rescue and risk of relapse in childhood acute lymphoblastic leukemia treated with high-dose methotrexate.","journal-title":"Pediatr Blood Cancer"},{"key":"ref=148","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1097\/MPH.0000000000001153","volume":"40","author":"Eldem I.","year":"2018","unstructured":"Eldem I, Yavuz D, Cumaogullari O, Ileri T, Unal Ince E, Ertem M, Doganay Erdogan B, Bindak R, Ozdag H, Satiroglu-Tufan NL, Uysal LZ. Slco1b1 polymorphisms are associated with drug intolerance in childhood leukemia maintenance therapy.","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref=149","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.leukres.2018.09.003","volume":"74","author":"De Carvalho D.C.","year":"2018","unstructured":"De Carvalho DC, Wanderley AV, Dos Santos AMR, Fernandes MR, Cohen Lima De Castro AN, Leitao LPC, De Carvalho JANJ, De Souza TP, Khayat AS, Dos Santos SEB, De Assumpcao PP, Dos Santos NPC. Pharmacogenomics and variations in the risk of toxicity during the consolidation\/maintenance phases of the treatment of pediatric b-cell leukemia patients from an admixed population in the brazilian amazon.","journal-title":"Leuk Res"},{"key":"ref=150","doi-asserted-by":"crossref","first-page":"5972","DOI":"10.1200\/JCO.2008.20.4156","volume":"27","author":"Trevino L.R.","year":"2009","unstructured":"Trevino LR, Shimasaki N, Yang W, Panetta JC, Cheng C, Pei D, Chan D, Sparreboom A, Giacomini KM, Pui CH, Evans WE, Relling MV. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.","journal-title":"J Clin Oncol"},{"key":"ref=151","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1182\/blood-2012-08-452839","volume":"121","author":"Ramsey L.B.","year":"2013","unstructured":"Ramsey LB, Panetta JC, Smith C, Yang W, Fan Y, Winick NJ, Martin PL, Cheng C, Devidas M, Pui CH, Evans WE, Hunger SP, Loh M, Relling MV. Genome-wide study of methotrexate clearance replicates slco1b1.","journal-title":"Blood"},{"key":"ref=152","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/FPC.0000000000000245","volume":"26","author":"Iparraguirre L.","year":"2016","unstructured":"Iparraguirre L, Gutierrez-Camino A, Umerez M, Martin-Guerrero I, Astigarraga I, Navajas A, Sastre A, Garcia de Andoin N, Garcia-Orad A. Mir-pharmacogenetics of methotrexate in childhood b-cell acute lymphoblastic leukemia.","journal-title":"Pharmacogenet Genomics"},{"key":"ref=153","first-page":"3144","volume":"62","author":"Chen Z.S.","year":"2002","unstructured":"Chen ZS, Lee K, Walther S, Raftogianis RB, Kuwano M, Zeng H, Kruh GD. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (abcc4): Mrp4 is a component of the methotrexate efflux system.","journal-title":"Cancer Res"},{"key":"ref=154","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0006-2952(02)01615-5","volume":"65","author":"Hooijberg J.H.","year":"2003","unstructured":"Hooijberg JH, Peters GJ, Assaraf YG, Kathmann I, Priest DG, Bunni MA, Veerman AJ, Scheffer GL, Kaspers GJ, Jansen G. The role of multidrug resistance proteins mrp1, mrp2 and mrp3 in cellular folate homeostasis.","journal-title":"Biochem Pharmacol"},{"key":"ref=155","doi-asserted-by":"crossref","first-page":"6914","DOI":"10.1073\/pnas.96.12.6914","volume":"96","author":"Kool M.","year":"1999","unstructured":"Kool M, Van Der Linden M, De Haas M, Scheffer GL, De Vree JM, Smith AJ, Jansen G, Peters GJ, Ponne N, Scheper RJ, Elferink RP, Baas F, Borst P. Mrp3, an organic anion transporter able to transport anti-cancer drugs.","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=156","first-page":"546","volume":"24","author":"Takatori R.","year":"2006","unstructured":"Takatori R, Takahashi KA, Tokunaga D, Hojo T, Fujioka M, Asano T, Hirata T, Kawahito Y, Satomi Y, Nishino H, Tanaka T, Hirota Y, Kubo T. Abcb1 c3435t polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients.","journal-title":"Clin Exp Rheumatol"},{"key":"ref=157","first-page":"4048","volume":"63","author":"Chen Z.S.","year":"2003","unstructured":"Chen ZS, Robey RW, Belinsky MG, Shchaveleva I, Ren XQ, Sugimoto Y, Ross DD, Bates SE, Kruh GD. Transport of methotrexate, methotrexate polyglutamates, and 17beta-estradiol 17-(beta-d-glucuronide) by abcg2: Effects of acquired mutations at r482 on methotrexate transport.","journal-title":"Cancer Res"},{"key":"ref=158","first-page":"5538","volume":"63","author":"Volk E.L.","year":"2003","unstructured":"Volk EL, Schneider E. Wild-type breast cancer resistance protein (bcrp\/abcg2) is a methotrexate polyglutamate transporter.","journal-title":"Cancer Res"},{"key":"ref=159","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/FPC.0b013e32835c3b24","volume":"23","author":"Lopez-Lopez E.","year":"2013","unstructured":"Lopez-Lopez E, Ballesteros J, Pinan MA, Sanchez de Toledo J, Garcia de Andoin N, Garcia-Miguel P, Navajas A, Garcia-Orad A. Polymorphisms in the methotrexate transport pathway: A new tool for mtx plasma level prediction in pediatric acute lymphoblastic leukemia.","journal-title":"Pharmacogenet Genomics"},{"key":"ref=160","doi-asserted-by":"crossref","first-page":"8661","DOI":"10.1158\/1078-0432.CCR-05-1096","volume":"11","author":"Plasschaert S.L.","year":"2005","unstructured":"Plasschaert SL, De Bont ES, Boezen M. vander Kolk, D.M.; Daenen, S.M.; Faber, K.N.; Kamps, W.A.; De Vries, E.G.; Vellenga, E. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia.","journal-title":"Clin Cancer Res"},{"key":"ref=161","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/tpj.2015.83","volume":"17","author":"Franca R.","year":"2017","unstructured":"Franca R, Rebora P, Bertorello N, Fagioli F, Conter V, Biondi A, Colombini A, Micalizzi C, Zecca M, Parasole R, Petruzziello F, Basso G, Putti MC, Locatelli F, d\u2019Adamo P, Valsecchi MG, Decorti G, Rabusin M. Pharmacogenetics and induction\/consolidation therapy toxicities in acute lymphoblastic leukemia patients treated with aieop-bfm all 2000 protocol.","journal-title":"Pharmacogenomics J"},{"key":"ref=162","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.clpt.2006.08.012","volume":"80","author":"Rau T.","year":"2006","unstructured":"Rau T, Erney B, Gores R, Eschenhagen T, Beck J, Langer T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: Impact of abcc2 polymorphisms on plasma concentrations.","journal-title":"Clin Pharmacol Ther"},{"key":"ref=163","doi-asserted-by":"crossref","first-page":"e82681","DOI":"10.1371\/journal.pone.0082681","volume":"9","author":"Liu Y.","year":"2014","unstructured":"Liu Y, Yin Y, Sheng Q, Lu X, Wang F, Lin Z, Tian H, Xu A, Zhang J. Association of abcc2 -24c>t polymorphism with high-dose methotrexate plasma concentrations and toxicities in childhood acute lymphoblastic leukemia.","journal-title":"PLoS One"},{"key":"ref=164","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3109\/08880018.2013.870625","volume":"31","author":"Sharifi M.J.","year":"2014","unstructured":"Sharifi MJ, Bahoush G, Zaker F, Ansari S, Rafsanjani KA, Sharafi H. Association of -24ct, 1249ga, and 3972ct abcc2 gene polymorphisms with methotrexate serum levels and toxic side effects in children with acute lymphoblastic leukemia.","journal-title":"Pediatr Hematol Oncol"},{"key":"ref=165","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1007\/s12185-013-1464-z","volume":"98","author":"Yanagimachi M.","year":"2013","unstructured":"Yanagimachi M, Goto H, Kaneko T, Naruto T, Sasaki K, Takeuchi M, Tanoshima R, Kato H, Yokosuka T, Kajiwara R, Fujii H, Tanaka F, Goto S, Takahashi H, Mori M, Kai S, Yokota S. Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy.","journal-title":"Int J Hematol"},{"key":"ref=166","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.gene.2017.07.025","volume":"628","author":"Gervasini G.","year":"2017","unstructured":"Gervasini G, de Murillo SG, Jimenez M, De La Maya MD, Vagace JM. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.","journal-title":"Gene"},{"key":"ref=167","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1182\/blood-2008-11-191098","volume":"114","author":"Ansari M.","year":"2009","unstructured":"Ansari M, Sauty G, Labuda M, Gagne V, Laverdiere C, Moghrabi A, Sinnett D, Krajinovic M. Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia.","journal-title":"Blood"},{"key":"ref=168","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00280-017-3340-7","volume":"80","author":"Mesrian Tanha H.","year":"2017","unstructured":"Mesrian Tanha H, Rahgozar S, Mojtabavi Naeini M. Abcc4 functional snp in the 3\u2032 splice acceptor site of exon 8 (g912t) is associated with unfavorable clinical outcome in children with acute lymphoblastic leukemia.","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=169","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/tpj.2014.63","volume":"15","author":"Den Hoed M.A.","year":"2015","unstructured":"Den Hoed MA, Lopez-Lopez E, Te Winkel ML, Tissing W, De Rooij JD, Gutierrez-Camino A, Garcia-Orad A, Den Boer E, Pieters R, Pluijm SM, De Jonge R, Van Den Heuvel-Eibrink MM. Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia.","journal-title":"Pharmacogenomics J"},{"key":"ref=170","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/tpj.2011.17","volume":"12","author":"Ansari M.","year":"2012","unstructured":"Ansari M, Sauty G, Labuda M, Gagne V, Rousseau J, Moghrabi A, Laverdiere C, Sinnett D, Krajinovic M. Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia.","journal-title":"Pharmacogenomics J"},{"key":"ref=171","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1126\/science.1168750","volume":"323","author":"Aller S.G.","year":"2009","unstructured":"Aller SG, Yu J, Ward A, Weng Y, Chittaboina S, Zhuo R, Harrell PM, Trinh YT, Zhang Q, Urbatsch IL, Chang G. Structure of p-glycoprotein reveals a molecular basis for poly-specific drug binding.","journal-title":"Science"},{"key":"ref=172","first-page":"2532","volume":"59","author":"Hooijberg J.H.","year":"1999","unstructured":"Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G. Antifolate resistance mediated by the multidrug resistance proteins mrp1 and mrp2.","journal-title":"Cancer Res"},{"key":"ref=173","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clpt.2003.09.012","volume":"75","author":"Marzolini C.","year":"2004","unstructured":"Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human mdr1 (p-glycoprotein): Recent advances and clinical relevance.","journal-title":"Clin Pharmacol Ther"},{"key":"ref=174","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1515\/dmpt-2015-0011","volume":"30","author":"Zaruma-Torres F.","year":"2015","unstructured":"Zaruma-Torres F, Lares-Asseff I, Reyes-Espinoza A, Loera-Castaneda V, Chairez-Hernandez I, Sosa-Macias M, Galaviz-Hernandez C, Almanza-Reyes H. Association of abcb1, abcc5 and xanthine oxidase genetic polymorphisms with methotrexate adverse reactions in mexican pediatric patients with all.","journal-title":"Drug Metab Pers Ther"},{"key":"ref=175","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1182\/blood-2012-07-440107","volume":"120","author":"Yang J.J.","year":"2012","unstructured":"Yang JJ, Cheng C, Devidas M, Cao X, Campana D, Yang W, Fan Y, Neale G, Cox N, Scheet P, Borowitz MJ, Winick NJ, Martin PL, Bowman WP, Camitta B, Reaman GH, Carroll WL, Willman CL, Hunger SP, Evans WE, Pui CH, Loh M, Relling MV. Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia.","journal-title":"Blood"},{"key":"ref=176","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/tpj.2014.81","volume":"15","author":"Gregers J.","year":"2015","unstructured":"Gregers J, Green H, Christensen IJ, Dalhoff K, Schroeder H, Carlsen N, Rosthoej S, Lausen B, Schmiegelow K, Peterson C. Polymorphisms in the abcb1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia.","journal-title":"Pharmacogenomics J"},{"key":"ref=177","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/sj.tpj.6500480","volume":"8","author":"Erdilyi D.J.","year":"2008","unstructured":"Erdilyi DJ, Kamory E, Csokay B, Andrikovics H, Tordai A, Kiss C, Filni-Semsei A, Janszky I, Zalka A, Fekete G, Falus A, Kovacs GT, Szalai C. Synergistic interaction of abcb1 and abcg2 polymorphisms predicts the prevalence of toxic encephalopathy during anticancer chemotherapy.","journal-title":"Pharmacogenomics J"},{"key":"ref=178","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1042\/bj20030150","volume":"373","author":"Mitomo H.","year":"2003","unstructured":"Mitomo H, Kato R, Ito A, Kasamatsu S, Ikegami Y, Kii I, Kudo A, Kobatake E, Sumino Y, Ishikawa T. A functional study on polymorphism of the atp-binding cassette transporter abcg2: Critical role of arginine-482 in methotrexate transport.","journal-title":"Biochem J"},{"key":"ref=179","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s00432-014-1670-y","volume":"140","author":"El Mesallamy H.O.","year":"2014","unstructured":"El Mesallamy HO, Rashed WM, Hamdy NM, Hamdy N. High-dose methotrexate in egyptian pediatric acute lymphoblastic leukemia: The impact of abcg2 c421a genetic polymorphism on plasma levels, what is next?","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=180","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00125817-200203000-00002","volume":"4","author":"Hirschhorn J.N.","year":"2002","unstructured":"Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies.","journal-title":"Genet Med"},{"key":"ref=181","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00228-013-1623-4","volume":"70","author":"Kodidela S.","year":"2014","unstructured":"Kodidela S, Suresh Chandra P, Dubashi B. Pharmacogenetics of methotrexate in acute lymphoblastic leukaemia: Why still at the bench level?","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=182","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2174\/138920009789375414","volume":"10","author":"Gervasini G.","year":"2009","unstructured":"Gervasini G. Polymorphisms in methotrexate pathways: What is clinically relevant, what is not, and what is promising.","journal-title":"Curr Drug Metab"},{"key":"ref=183","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1371\/journal.pmed.0050083","volume":"5","author":"Sorich M.J.","year":"2008","unstructured":"Sorich MJ, Pottier N, Pei D, Yang W, Kager L, Stocco G, Cheng C, Panetta JC, Pui CH, Relling MV, Cheok MH, Evans WE. response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile.","journal-title":"PLoS Med"},{"key":"ref=184","author":"Zhang B.","year":"2019","unstructured":"Zhang B, Lauschke VM. Genetic variability and population diversity of the human slco (oatp) transporter family.","journal-title":"Pharmacol Res"},{"key":"ref=185","first-page":"1339","volume":"15","author":"Udagawa C.","year":"2018","unstructured":"Udagawa C, Sasaki Y, Suemizu H, Ohnishi Y, Ohnishi H, Tokino T, Zembutsu H. Targeted sequencing reveals genetic variants associated with sensitivity of 79 human cancer xenografts to anticancer drugs.","journal-title":"Exp Ther Med"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/169486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T13:44:17Z","timestamp":1720964657000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/169486\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,11]]},"references-count":185,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,6,11]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389200220666190130161758","relation":{},"ISSN":["1389-2002"],"issn-type":[{"value":"1389-2002","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6,11]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-11-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-11","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-06-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}